Liminatus Pharma, Inc.
LIMN Nasdaq
SEC CIK 1971387
Follow Liminatus Pharma
Weekly email: filings, results
Net income
−$1.4M
−1342.2% vs same quarter last year
EPS, diluted
−$0.03
Operating cash flow
−$970K
+89% vs same quarter last year
Operating income
−$1.4M
−23.3% vs same quarter last year
Source: SEC XBRL filings · latest filing